Marksans Pharma Ltd Board of Directors
Board of Directors at Marksans Pharma Ltd
Non-Exec. & Independent Dir.
Non-Exec. & Independent Dir.
Company Sec. & Compli. Officer
Chairman & Managing Director
Whole-time Director
Key Highlights
- Mark Saldanha joins the board as CMD & Executive Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Sandra Saldanha joins the board as Whole Time Executive Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Varddhman Vikramaditya Jain joins the board as Non Independent Executive Director / WTD, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Digant Mahesh Parikh joins the board as Independent Non Exe. Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
- Abhinna Sundar Mohanty joins the board as Independent Non Exe. Director, in a new position in 2026. This addition introduces a dedicated role focused on the company’s day-to-day operations and strategic implementation.
Marksans Pharma Ltd
NSE: MARKSANS
Share Price
Last Ten Days Market Price
| Date | |
|---|---|
| 30 Sep 2026 | 322.25 |
| 29 Sep 2026 | 342.8 |
| 28 Sep 2026 | 331.6 |
| 25 Sep 2026 | 336.9 |
| 24 Sep 2026 | 337.6 |
| 23 Sep 2026 | 347.45 |
| 22 Sep 2026 | 332.6 |
| 21 Sep 2026 | 338.15 |
| 18 Sep 2026 | 319.8 |
| 17 Sep 2026 | 319.15 |
Company Fundamentals for Marksans Pharma Ltd
Market Cap
15,534 Cr
EPS
11.4
P/E Ratio (TTM)
30.1
P/B Ratio (TTM)
5.1
Day’s High
345.9
Day’s Low
321.0
DTE
0.1
ROE
13.8
52 Week High
350.75
52 Week Low
156.0
ROCE
17.4
Market Price of Marksans Pharma Ltd
1M
1Y
3Y
5Y
Marksans Pharma Ltd News Hub
Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules
Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketing Authoriz
Read more
21 Aug 24
Marksans Pharma gets EIR from USFDA for Goa facility
The inspection has been classified as voluntary action indicated (VAI) and has been closed according
Read more
20 Aug 24
Marksans Pharma's Verna unit successfully completes USFDA inspection
Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its
Read more
20 Aug 24
Marksans Pharma to convene AGM
Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 Se
Read more
20 Aug 24
